AI + Health

[chris macrae]

43 years ago economist survey on health (1984) recommended everywhere trach affordability of health as major reason for accelerating tech including ai
this hasnt happened especially in west AI + Health has become one of the most complex challenges to mediate - it would really help with nvidia partnership with euro broadcaster got serious about health and intelligence everyone needs to integrate layer 5 ai
question to Gemini - top 20 nvidia ai plarfoems
when you put alongside clara platform healthcare imaging - is this mainly radiology
Yes, it is primarily centered on radiology, but it has actively expanded to cover other visual and scanning medical modalities. [1, 2]
While traditional applications of NVIDIA Clara and its underlying MONAI framework targeted high-volume structural scans like CT, MRI, X-ray, and ultrasound (the core domain of radiologists), the platform explicitly encompasses multi-modal diagnostics: [1, 2]
• Digital Pathology: Analyzing gigapixel Whole Slide Images (WSIs) of tissue samples for cellular anomalies and oncology.
• Endoscopy & Surgery: Processing live, frame-by-frame internal video feeds during operations for real-time lesion or boundary detection.
• Genomics & Molecular Imaging: Crossing visual spatial data with NVIDIA Parabricks for sequencing overlays, though heavy molecular compound generation is typically handed off to BioNeMo. [1, 2, 3]
Would you like to examine how multimodal vision-language models like Clara Reason bridge radiology image sets with textual electronic health records (EHRs) for automated clinical reporting? [1, 2]
This is for informational purposes only. For medical advice or diagnosis, consult a professional. AI responses may include mistakes. Learn more
•
NVIDIA Developer
NVIDIA Clara Platform: Augmenting Radiology with AI
Mar 11, 2019 — ... and making interpretations more intuitive. AI-generated content may summarize information incompletely. Verify important infor...

•

LinkedIn·Pallavi N.
NVIDIA Clara Imaging: The Complete Technical Teardown
May 18, 2026 — It's a family of open-source AI models, frameworks, tools, and deployment infrastructure specifically designed for medical imaging...

•
Radiology Business
Nvidia rolls out AI models designed to behave like radiologists ...
Nov 4, 2025 — Nvidia rolls out AI models designed to behave like radiologists interpreting images. ... Nvidia—a leader in artificial intelligenc...

Show all
nvidia has been connecyted radilogu for nearly 20 years before clara platform identified- does clara include biotech too- is nvidia partnership with recursion going well
Yes, NVIDIA was embedded in radiology long before the Clara platform was identified, and the modern Clara ecosystem has successfully expanded into deep biotechnology. [1, 2, 3]
NVIDIA spent nearly two decades as an underlying hardware driver for healthcare imaging before establishing its current brand hierarchy. The long-term journey of its health platforms and its strategic partnership with Recursion Pharmaceuticals highlights this evolution. [1, 2, 3]
________________________________________
⏱️ The 20-Year Evolution: From Hardware Engine to Clara
NVIDIA's legacy in medical imaging dates back to the early 2000s, well before artificial intelligence dominated the clinical conversation: [1]
• The Pre-AI Era (2006–2015): Long before Clara launched in 2018, medical device giants like GE HealthCare, Siemens, and Philips used NVIDIA GPUs purely to process heavy 3D pixel mathematics. Without GPUs, processing raw radiation data from a CT scan or radio frequencies from an MRI into a readable 3D visual layer would take hours instead of seconds.
• The Birth of Clara: By 2018, NVIDIA realized it was no longer just providing basic computer chips to imaging machines. It bundled its medical imaging toolsets, AI processing, and real-time visualization frameworks into the singular NVIDIA Clara platform. [1, 2]
________________________________________
🧬 Does Clara Include Biotech?
Yes. NVIDIA Clara is not just a radiology application; it is an overarching umbrella brand containing four highly specialized pillars, half of which are built exclusively for biotechnology, pharma, and genomics: [1, 2, 3]
┌─────────────────────────────────────────┐ │ NVIDIA CLARA │ └────────────────────┬────────────────────┘ │ ┌──────────────────────────────────┴──────────────────────────────────┐ ▼ ▼ [ CLINICAL DATA LAYERS ] [ BIOTECHNOLOGY LAYERS ] ┌──────────────────────────────┐ ┌──────────────────────────────┐ │ MONAI / Clara Imaging │ │ BioNeMo │ │ (Radiology, Pathology, WSIs) │ │ (Digital Biology & Chemistry)│ └──────────────────────────────┘ └──────────────────────────────┘ ┌──────────────────────────────┐ ┌──────────────────────────────┐ │ Holoscan │ │ Parabricks │ │ (Medical Devices & Surgery) │ │ (Ultra-Fast DNA Sequencing) │ └──────────────────────────────┘ └──────────────────────────────┘
1. BioNeMo (The Biotech Engine): This is NVIDIA’s generative AI cloud service built explicitly for computer-aided drug discovery. It handles molecular modeling, generative protein design, and chemical text notation. [1, 2, 3, 4]
2. Parabricks (The Genomics Engine): A heavy biotech compute framework capable of sequencing an entire human genome in under 20 minutes—slashing time-to-insight for geneticists and precision medicine researchers. [1]
________________________________________
💊 Is the NVIDIA Partnership with Recursion Going Well?
The commercial relationship between NVIDIA and Recursion Pharmaceuticals (RXRX) is highly active on a technical level, though it has evolved into a pure enterprise software relationship. [1, 2]
1. The Technical Execution is Exploding
On an operational level, the partnership is achieving historic computational scales:
• BioHive-2 Supercomputer: NVIDIA and Recursion quadrupled the power of Recursion's native infrastructure, building BioHive-2. It stands as the most powerful AI supercomputer owned and operated by any biopharma company globally. [1, 2]
• Open-Source Foundations: The partnership recently yielded Boltz-2 (developed alongside MIT), a fully open-source biomolecular foundation model that predicts protein-complex binding affinities with physics-level accuracy. [1]
• BioNeMo Distribution: Recursion continues to publish its proprietary data foundation models, such as its Phenom phenomics series, hosted directly inside the NVIDIA BioNeMo framework for broader biotech utilization. [1]
2. The Financial Pivot: NVIDIA Fully Exited the Stock [1]
Despite the collaborative technical milestones, NVIDIA altered its financial position in early 2026. In its 13F financial filing, NVIDIA disclosed it had completely liquidated its 7.7 million share equity stake in Recursion. [1, 2]
• The Market Dynamic: This move sparked sharp debates in Wall Street's TechBio sectors. Because Recursion is a late-stage, private-to-public transition company that has yet to commercialize a fully approved drug independently, critics viewed NVIDIA’s stock exit as a sign that drug discovery pipelines take longer to mature than software loops. [1, 2, 3, 4, 5]
• The Strategic Reality: NVIDIA’s equity exit does not break the partnership. It simply shows Jensen Huang's preference for acting as an infrastructure provider and software licensor rather than a long-term equity holder in individual biotech firms. NVIDIA provides the pickaxes (DGX Cloud and BioNeMo NIMs); they are content letting entities like Recursion and its pharma partners (like Bayer) take on the direct clinical development risks. [1, 2, 3, 4, 5]
Would you like to examine how Recursion leverages NVIDIA software to power its "self-driving, automated wet laboratories" via robotic orchestration and digital twins? [1, 2]
•
NVIDIA Blog
Drug Discovery, STAT! NVIDIA, Recursion Speed Pharma ...
May 13, 2024 — The resulting NVIDIA DGX SuperPOD is nearly 5x faster than Recursion's first-generation system, BioHive-1. Performance Powers Thro...

•
www.recursion.com
Nothing Short of Phenomenal: New Deep Learning Model ...
Jan 9, 2024 — Recursion is releasing the first in a potential series of foundation models for external use, hosted on the NVIDIA BioNeMo platfor...

•
NVIDIA
MIT and Recursion Launch Open-Source Protein Co ... - NVIDIA
Overview. MIT's Jameel Clinic and CSAIL researchers, partnering with Recursion, built Boltz 2. This first fully open-source biomol...

Show all
Are isomoehics of google deep mind and recursion head on heaf competitors
Yes, Isomorphic Labs (Alphabet/Google DeepMind’s AI drug discovery spinout) and Recursion Pharmaceuticals are head-on, direct competitors in the elite tier of AI-driven drug design and TechBio. [1, 2, 3]
Both companies are racing to fundamentally disrupt traditional pharmaceutical pipelines by replacing trial-and-error laboratory work with deep learning simulations. However, they approach the market with distinct operational strategies: [1]
• Isomorphic Labs (The Pure-Play AlphaFold Descendant): Backed by massive Alphabet capital (including a staggering $2.1 billion funding round), Isomorphic behaves less like a traditional biotech and more like an elite software/infrastructure provider. Leveraging the revolutionary architecture of AlphaFold, they secure high-value commercial partnerships with pharma giants like Eli Lilly, focusing heavily on computational precision and physics-level target predictions without being weighed down by massive physical wet-lab footprints. [1, 2, 3, 4, 5]
• Recursion Pharmaceuticals (The Automated Lab Industrialist): Recursion operates as a publicly traded TechBio pioneer that pairs high-throughput supercomputing (via systems like BioHive-2) with immense, proprietary physical automated "wet laboratories". While they partner widely across the tech ecosystem (including with NVIDIA and major pharma like Bayer), their strategy leans into physical-to-digital integration, trying to industrialize the actual generation of biological training data at a massive scale. [1, 2, 3, 4]
If you'd like, we can analyze how Isomorphic Labs' reliance on Google's TPU infrastructure compares to Recursion's hardware stack following NVIDIA's recent shifts in equity positioning.
•
New Market Pitch
AI Drug Discovery: what are the top startups now?
Jun 29, 2026 — The strongest top tier today is Isomorphic Labs, Insilico Medicine, Recursion, Chai Discovery, and Genesis Therapeutics. The marke...

•
Yahoo Finance
Recursion Pharmaceuticals vs. Schrödinger: Which Healthcare ...
Jun 2, 2026 — Schrödinger: Which Healthcare Stock Is a Better Buy in 2026? ... As drug discovery moves from trial-and-error to digital simulatio...

•
Pharmaceutical Technology
Big tech meets biotech: Recursion and the AI gold rush in pharma
Mar 18, 2025 — As AI reshapes drug discovery and development, Recursion Pharmaceuticals is tapping into its potential. ... Recursion utilises mac...

[chris macrae]

Can you tell me about siemens healthineers- i know siemens been loyal partner of nvidai industrail revolution 4- but what are helathineers aiming to innovate

Siemens Healthineers is focusing its innovation strategy on transitioning from isolated, diagnostic medical devices into integrated, end-to-end "Patient Twinning" systems and AI-guided therapy workflows. [1, 2, 3]

While its parent company, Siemens AG, collaborates with NVIDIA to build massive Industrial AI Operating Systems, factory humanoids, and digital twin factories for sectors like automotive and semiconductors, Siemens Healthineers applies this same Industrial Revolution 4.0 computing power directly to the human body. [1, 2, 3, 4, 5]

🔬 Core Innovation Pillars of Siemens Healthineers

Rather than merely selling faster MRI or CT hardware, Healthineers aims to revolutionize care through three strategic initiatives: [1, 2, 3]

1. Real-Time "Patient Twinning" (Comprehensive Digital Health Replicas) [1, 2, 3]

• The Innovation: Building a dynamic, multi-modal Digital Twin of the patient.
• How it Works: By pulling a patient’s cross-sectional radiology scans, digital pathology slides, genetic sequencing markers, and electronic health records into a single compute model, physicians can run virtual simulations. For complex oncology cases, teams can simulate radiation trajectories or drug dosages on the digital twin to predict side effects and efficacy before treating the actual patient. [1, 2, 3]

2. AI-Driven Adaptive Therapeutics (Interventional Automation)

• The Innovation: Merging robotic physical mechanics with live AI vision during active surgical and interventional procedures.
• How it Works: Next-generation platforms like the ARTIS genio (angiography) and ARTIS pheno vision use embedded, GPU-accelerated edge AI. During a stroke intervention or cardiac catheterization, the imaging system automatically tracks and highlights arterial boundaries, adjusts radiation exposure dynamically, and guides the surgeon’s instruments with millimeter-level robotic precision. [1, 2, 3]

3. Low-Field Accessible MRI (Democratizing Imaging)

• The Innovation: Disrupting traditional high-maintenance imaging with the MAGNETOM Free low-field MRI ecosystem.
• How it Works: Traditional high-field MRIs require massive amounts of liquid helium for cooling and specialized, reinforced rooms. By utilizing heavy deep-learning reconstruction algorithms, Healthineers can capture high-fidelity diagnostic images using much smaller, helium-free magnetic fields. This allows advanced MRI diagnostic capabilities to be deployed in remote clinics, emergency rooms, and developing nations where traditional infrastructure is impossible to maintain. [1, 2, 3, 4, 5]

🔄 The Technological Convergence: Siemens AG vs. Siemens Healthineers

Dimension	Siemens AG (Industrial / Corporate)	Siemens Healthineers (MedTech Ecosystem)
Core Architecture	Siemens Digital Twin Composer & Omniverse.	Multi-Modal Patient Twins and Clinical AI.
Primary Target	Factories, semiconductor chips, and supply chains.	Hospitals, oncology wards, and interventional suites.
NVIDIA Interface	Physical AI factory brains and industrial copilots.	NVIDIA Clara frameworks embedded directly into scanner hardware.

Would you like to examine how Siemens Healthineers integrates NVIDIA's MONAI framework directly into their ARTIS robotic imaging platforms to automate cancer tumor segmentation in real time?

LinkedIn·AIM

Siemens & NVIDIA Expand AI Partnership for Industrial ...

Jan 6, 2026 — Roland Busch, President and CEO of Siemens AG, said, "Together, we are building the Industrial AI operating system — redefining ho...

Siemens press

Siemens and NVIDIA expand partnership to build the ...

Jan 6, 2026 — Together, the companies aim to accelerate deployment, increase energy efficiency, and improve resilience for industrial-scale AI i...

Siemens Newsroom

Siemens unveils industrial AI innovations at CES 2026

Jan 14, 2026 — Siemens and NVIDIA expand their partnership to build the Industrial AI Operating System, reinventing the entire end-to-end industr...

Show all